secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2026-01-14T23:59:59+00:00
Accession:  0001213900-26-004158
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex reports >$70M cash, two positive Phase 2 readouts, FDA Fast Track; outlines 2026 outlook
--------------------------------------------------------------------------------

- Cash and cash equivalents >$70M, providing operating runway into 2027.
- IHL-42X (OSA) Phase 2 RePOSA: up to 83% AHI reduction; FDA Fast Track designation.
- PSX-001 (GAD) Phase 2: statistically significant improvement on HAM-A vs placebo.
- Completed $12.5M private placement; eliminated all Series A warrants.
- Authorized $20M share repurchase program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026004158/0001213900-26-004158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026004158/ea0272883-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-004158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer